Researchers identified five genes related to fat attachment to proteins that could help doctors diagnose atherosclerosis earlier. According to Gram Research analysis, these genes—PLCB2, GMIP, NEXN, PLN, and SLC7A7—showed strong ability to identify heart artery disease in validation datasets, with findings confirmed in mice. One gene, SLC7A7, appeared to have protective effects against the disease. However, this discovery is still in early research stages and requires human clinical trials before doctors can use it for patient diagnosis.
Scientists discovered five special genes that could help doctors identify atherosclerosis—a disease where fatty buildup clogs heart arteries—much earlier and more accurately. According to Gram Research analysis, these genes are involved in how fat gets attached to proteins in cells, which affects inflammation and blood vessel health. The researchers tested their findings in mice and human tissue samples, and the results were consistent across multiple datasets. This discovery could lead to better ways to diagnose and treat this serious heart condition before it causes major problems.
Key Statistics
A 2026 research article identified five palmitoylation-related genes (PLCB2, GMIP, NEXN, PLN, and SLC7A7) that showed strong diagnostic performance for atherosclerosis when tested on independent human tissue datasets.
In mice with atherosclerosis, three of the five genes were overactive while two were underactive, exactly matching predictions from human tissue analysis, demonstrating consistency between laboratory findings and animal models.
Single-cell analysis revealed that different genes were active in different cell types: immune genes (PLCB2 and GMIP) were expressed in T cells and macrophages, while muscle genes (NEXN and PLN) were enriched in vascular smooth muscle cells.
Mendelian randomization analysis suggested SLC7A7 has a potential protective causal association with atherosclerosis, distinguishing it from genes merely associated with the disease.
The Quick Take
- What they studied: Whether certain genes related to a process called palmitoylation (how fat attaches to proteins) could be used as early warning signs for atherosclerosis, the buildup of plaque in arteries.
- Who participated: The study analyzed genetic data from multiple human tissue databases and tested findings in laboratory mice bred to develop atherosclerosis when fed a high-fat diet.
- Key finding: Five genes—PLCB2, GMIP, NEXN, PLN, and SLC7A7—showed strong ability to identify atherosclerosis in validation datasets, with one gene (SLC7A7) appearing to have protective effects against the disease.
- What it means for you: These genes could eventually become part of a blood test to catch heart artery disease early, before symptoms appear. However, this research is still in early stages and needs more testing in humans before doctors can use it clinically.
The Research Details
Researchers used a detective-like approach to find genes linked to atherosclerosis. They started with genetic information from two large human tissue databases (GSE100927 and GSE43292), comparing genes that were turned on or off differently in diseased versus healthy tissue. They then filtered these genes to focus only on ones involved in palmitoylation—a process where fat molecules stick to proteins, affecting how cells work.
To narrow down their findings, they used two different computer methods (random forest and support vector machine) to identify the most important genes. They also used a technique called Mendelian randomization to determine which genes might actually cause atherosclerosis versus just being associated with it. Finally, they tested their top five genes in mice that naturally develop atherosclerosis when fed a high-fat diet, and confirmed the genes behaved the same way in mouse tissue as predicted.
This multi-step approach is important because it combines computer analysis of human genetic data with real-world testing in animals. This makes the findings more trustworthy than if researchers had only looked at one type of data. The use of external validation datasets means the results weren’t just a lucky finding in one group of people—they held up when tested on different groups.
Strengths include validation across multiple independent datasets, confirmation in animal models, and use of established statistical methods. The study identified genes with specific cell locations (immune cells and blood vessel cells), which makes biological sense. Limitations include that this is laboratory research not yet tested in living humans, the sample size from the original datasets isn’t specified, and the findings need confirmation in clinical trials before doctors can use them for patient care.
What the Results Show
The researchers identified 51 genes related to palmitoylation that were abnormally active in atherosclerosis tissue. Through careful filtering, they narrowed this to five key genes: PLCB2, GMIP, NEXN, PLN, and SLC7A7. These five genes performed well at identifying atherosclerosis in a separate validation dataset, suggesting they could work as diagnostic markers.
When they created a diagnostic tool (nomogram) using these five genes, it accurately classified atherosclerosis cases and showed good performance across different patient groups. The tool was well-calibrated, meaning its predictions matched real-world outcomes.
In mice with atherosclerosis, three genes (PLCB2, GMIP, and SLC7A7) were overactive, while two genes (NEXN and PLN) were underactive—exactly matching what the human tissue analysis predicted. This consistency between human data and animal models strengthens confidence in the findings.
The research revealed that these five genes work through several interconnected pathways: immune system activation (both the innate and adaptive immune responses), calcium signaling (important for heart muscle function), changes in the extracellular matrix (the structural scaffolding around cells), cell-to-cell communication, and autophagy (cellular cleanup processes). At the single-cell level, different genes were active in different cell types—immune cells showed high activity of PLCB2 and GMIP, while blood vessel smooth muscle cells showed high activity of NEXN and PLN. This cell-type specificity suggests each gene plays a distinct role in different parts of the atherosclerosis process.
This study builds on existing knowledge that inflammation and immune dysfunction drive atherosclerosis. Previous research identified palmitoylation as important for cell signaling, but this is one of the first studies to systematically map which palmitoylation-related genes matter most in atherosclerosis and to validate findings across multiple datasets and in animal models. The identification of SLC7A7 as potentially protective is novel and could open new treatment directions.
The study is primarily computational and animal-based; human clinical trials are needed to confirm these genes work as biomarkers in real patients. The original sample sizes from the genetic databases aren’t clearly specified. The findings come from tissue samples, not blood tests, so it’s unclear if these genes could be detected in blood for practical clinical use. The study doesn’t explain exactly how these genes cause atherosclerosis, only that they’re associated with it. Finally, the mouse model uses genetically modified mice on high-fat diets, which may not perfectly represent atherosclerosis in humans with different genetic backgrounds and lifestyles.
The Bottom Line
This research is promising but preliminary. It should not yet change how doctors diagnose or treat atherosclerosis. The findings suggest that a blood test measuring these five genes could eventually help identify people at high risk for heart artery disease, but this needs testing in human clinical trials first. People concerned about heart disease should continue following established prevention strategies: maintain a healthy weight, exercise regularly, eat a heart-healthy diet low in saturated fat, don’t smoke, and manage stress. Talk to your doctor about your personal risk factors.
This research is most relevant to cardiologists, researchers studying heart disease, and people with family histories of early heart disease. It’s not yet applicable to the general public for personal health decisions. People with existing atherosclerosis or high cholesterol should continue their current medical treatment while this research advances.
If these genes prove useful in human trials, it would likely take 5-10 years before a commercial blood test becomes available. Even then, the test would probably be used alongside existing risk assessments, not as a replacement. Benefits would be earlier detection and potentially earlier treatment, but this timeline is speculative.
Frequently Asked Questions
Can a blood test for these five genes predict if I’ll get heart disease?
Not yet. This research identified five genes that appear linked to atherosclerosis in tissue samples and mice, but clinical trials in humans are needed first. Current blood tests measuring cholesterol and other traditional risk factors remain the standard for heart disease prediction.
What does palmitoylation have to do with clogged arteries?
Palmitoylation is when fat molecules attach to proteins, affecting how cells function. This study found that problems with palmitoylation trigger inflammation and immune system dysfunction, which are key drivers of atherosclerosis development and progression.
If SLC7A7 is protective against atherosclerosis, could it become a treatment?
Possibly, but that’s years away. The study found SLC7A7 appears protective, suggesting it could be a drug target. However, researchers would need to understand exactly how it works and then develop and test treatments in humans—a process taking many years.
How soon will doctors use these genes to diagnose heart disease?
Likely 5-10 years minimum. The research is promising but still in early stages. It needs human clinical trials to confirm these genes work as biomarkers in real patients before any commercial test becomes available.
Should I change my diet or exercise based on this research?
Not based on this study alone. Continue following established heart disease prevention: regular exercise, heart-healthy diet, healthy weight, no smoking, and stress management. Talk to your doctor about your personal risk factors and prevention strategies.
Want to Apply This Research?
- Once these genes become clinically available, users could track their gene expression levels (if offered through their doctor) alongside traditional heart disease risk factors like cholesterol levels, blood pressure, and weight. This would create a comprehensive cardiovascular health profile.
- Users could use the app to log lifestyle factors known to reduce atherosclerosis risk—daily exercise minutes, servings of vegetables, saturated fat intake, and stress management activities—and correlate these behaviors with any future biomarker testing results to see which changes have the most impact.
- Establish a baseline assessment of traditional cardiovascular risk factors (cholesterol, blood pressure, weight, family history) and track changes quarterly. Once gene-based testing becomes available, integrate those results into the app’s risk assessment algorithm to provide personalized recommendations for diet, exercise, and medical follow-up.
This research is preliminary and has not yet been tested in human clinical trials. The findings are based on tissue sample analysis and animal models, not human patients. These genes should not be used for personal health decisions or medical diagnosis at this time. Anyone concerned about heart disease risk should consult with their healthcare provider about established screening methods and prevention strategies. This article is for educational purposes only and does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
